Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 11/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | FSHR | P23945 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23711614 | 0.71 | PIK3C3 (0.40) | TSHRMEN1RAB9AKMT2A | |
| SCHEMBL20542063 | 0.71 | CA1 (0.40) | MAPKAPK2MAP4K4TSHRMEN1KMT2A | |
| SCHEMBL25480032 | 0.69 | PIK3C3 (0.38) | TSHRMEN1KMT2A | |
| SCHEMBL14854850 | 0.68 | TSHR (0.43) | MAPKAPK2MAP4K4TSHRFSHRCA1 | |
| SCHEMBL23094457 | 0.68 | TKT (0.48) | MAPKAPK2MAP4K4TSHRFSHRSYK | |
| SCHEMBL20087958 | 0.67 | ATR (0.44) | MAPKAPK2GSK3BDYRK1AMEN1NPC1 | |
| SCHEMBL7050966 | 0.67 | LCK (0.40) | MAP4K4GSK3BDYRK1AMEN1NPC1 | |
| SCHEMBL28255203 | 0.66 | CTSK (0.40) | NPC1RAB9ACA1CA2NAMPT | |
| SCHEMBL21450373 | 0.66 | MAPKAPK2 (0.47) | MAPKAPK2MAP4K4GSK3BDYRK1A | |
| SCHEMBL5838255 | 0.65 | ATR (0.47) | MAPKAPK2MAP4K4TSHRFSHRGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131192-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131192-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | MAPKAPK2 551/4885MAP4K4 685/4885TSHR 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.